Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41418-021-00844-6 http://scihub22266oqcxt.onion/10.1038/s41418-021-00844-6 34404919!8370058!34404919     free     free     free       Cell+Death+Differ 2022 ; 29 (1): 156-166 Nephropedia Template TP {{tp|p=34404919|t=2022. Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection |pdf=|usr=}}{{34404919}} gab.com Text Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection JO: Cell Death Differ http://www.kidney.de/pget.php?&tw=1&pmid=34404919 #FOAvip The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rate of the virus, which would require unusually high protection by a vaccine. Here, we show how raloxifene, a selective estrogen receptor modulator with anti-inflammatory and antiviral properties, emerges as an attractive candidate entering clinical trials to test its efficacy in early-stage treatment COVID-19 patients. Twit Text FOAVip Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection ????Cell Death Differ http://www.kidney.de/pget.php?&tw=1&pmid=34404919 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34404919 #FOAvip English Wikipedia <ref>{{Cite pmid|34404919}}</ref> Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection #MMPMID34404919 Allegretti M; Cesta MC; Zippoli M; Beccari A; Talarico C; Mantelli F; Bucci EM; Scorzolini L; Nicastri E Cell Death Differ 2022[Jan]; 29 (1): 156-166 PMID34404919show ga The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rate of the virus, which would require unusually high protection by a vaccine. Here, we show how raloxifene, a selective estrogen receptor modulator with anti-inflammatory and antiviral properties, emerges as an attractive candidate entering clinical trials to test its efficacy in early-stage treatment COVID-19 patients. |*COVID-19 Drug Treatment[MESH] |*Drug Repositioning[MESH] |Angiotensin-Converting Enzyme 2/metabolism[MESH] |Anti-Inflammatory Agents/*therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |Estradiol/therapeutic use[MESH] |Estrogen Receptor Modulators/*therapeutic use[MESH] |Estrogens/metabolism[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Raloxifene Hydrochloride/*therapeutic use[MESH] |SARS-CoV-2/drug effects[MESH]Repurposing the estrogen receptor modulator raloxifene to treat SARS-C(epmc).pdf DeepDyve Pubget Overpricing